Introduction to Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market :
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that primarily affects the lungs and liver. It is characterized by a deficiency in the alpha-1 antitrypsin protein, which plays a crucial role in protecting the lungs from damage caused by enzymes like neutrophil elastase. Without sufficient alpha-1 antitrypsin, individuals with AATD are at a heightened risk of developing lung diseases, particularly chronic obstructive pulmonary disease (COPD), and liver conditions.
The global alpha-1 antitrypsin deficiency augmentation therapy market size is expected to be worth around USD 2517 Mn by 2032 from USD 1,413 Mn in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032.
For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2032 – Please check this report:https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-the...
Fastest Growing Market:
Increasing Prevalence and Awareness:
Rising awareness about Alpha-1 Antitrypsin Deficiency (AATD) is leading to more diagnoses, thereby increasing the demand for augmentation therapy.
The prevalence of AATD is on the rise due to improved genetic testing and screening methods.
Growing Patient Pool:
The expanding population of AATD patients, especially in regions with a higher genetic predisposition, is a driving factor for market growth.
Early diagnosis and treatment initiation are becoming more common, further boosting the patient pool.
Market Regional Analysis:
-North America [United States, Canada, Mexico]
-South America [Brazil, Argentina, Columbia, Chile, Peru]
-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
-Middle East & Africa [GCC, North Africa, South Africa]
-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Market Key Players:
Grifols, S.A. (Spain)
Kamada Pharmaceuticals
CSL Limited
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries ltd.
GlaxoSmithKline PLC
Arrowhead Pharmaceutical, Inc.
LFB Biomedicaments S.A.
Mereo BioPharma Group plc
Intellia Therapeutics, Inc.
Inhibrx, Inc.
Centessa Pharmaceuticals (Z factor)
Krystal Biotech
Beam Therapeutics
LOGICBIO THERAPEUTICS, INC.
Apic Bio
Pfizer Inc.
Other Key Players
Market Top Segmentations:
Based on Product Type
Prolastin C
Aralast NP
Glassia
Zemaira/Respreeza
Based on End-User
Hospitals
Specialty Clinics
Pharmacies
Make an inquiry before picking up this report @https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-the...
Challenges and Opportunities:
Challenges:
High Treatment Costs:
Challenge: Augmentation therapy can be expensive, posing affordability issues for some patients and healthcare systems.
Lifelong Therapy Requirement:
Challenge: AATD patients typically require lifelong therapy, which can be logistically and financially burdensome.
Opportunities:
Rising AATD Prevalence:
Opportunity: The increasing prevalence of AATD due to improved diagnosis creates a larger patient pool for augmentation therapy.
Innovations in Therapy:
Opportunity: Ongoing research and development efforts offer opportunities to create more effective and convenient augmentation therapies.
Contact:
Global Business Development Team – Market.us
Market.us (Powered by Prudour Pvt. Ltd.)
Send Email: inquiry@market.us
Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States
Tel: +1 718 618 4351
Website: https://market.us